Effect of an inhaled adenosine A₂A agonist on the allergen-induced late asthmatic response

Adenosine receptor activation is suggested to play a role in asthmatic airway inflammation. Inhibition of adenosine receptors may have an effect on the late asthmatic response (LAR) after allergen inhalation and this mechanism could offer a potential new treatment in asthma. We evaluated the effect...

Full description

Saved in:
Bibliographic Details
Published in:Allergy (Copenhagen) 2008, Vol.63 (1), p.75-80
Main Authors: Luijk, B, van den Berge, M, Kerstjens, H.A.M, Postma, D.S, Cass, L, Sabin, A, Lammers, J.-W.J
Format: Article
Language:English
Subjects:
adenosine
Adenosine A2 Receptor Antagonists
adenosine-₂A agonist
adenosine‐2A agonist
Administration, Inhalation
Adolescent
Adult
airway inflammation
allergen
Allergens
Androstadienes - administration & dosage
Anti-Asthmatic Agents - administration & dosage
asthma
Asthma - diagnosis
Asthma - drug therapy
Asthma - immunology
Bronchial Provocation Tests
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Fluticasone
Follow-Up Studies
Humans
Male
Middle Aged
Multivariate Analysis
Probability
Reference Values
Respiratory Function Tests
Risk Assessment
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adenosine receptor activation is suggested to play a role in asthmatic airway inflammation. Inhibition of adenosine receptors may have an effect on the late asthmatic response (LAR) after allergen inhalation and this mechanism could offer a potential new treatment in asthma. We evaluated the effect of an inhaled adenosine-₂A (A₂A)-receptor agonist (GW328267X), 25 μg, in 15 nonsmoking atopic asthmatics who underwent an inhaled allergen challenge following twice daily treatment for 1 week in a double-blind, placebo- and fluticasone propionate (250 μg) controlled study. In contrast to fluticasone, treatment with the A₂A-receptor agonist neither significantly protect against the allergen-induced early and late asthmatic reaction, nor the accompanying inflammatory response as measured by sputum total cell counts, number of EG2+ cells, and the concentration of interleukin-8 and eosinophil cationic protein. The inhaled A₂A-receptor agonist, GW328267X, 25 μg does not affect the allergen-induced LAR or the associated inflammatory response in asthma.
ISSN:0105-4538
1398-9995
DOI:10.1111/j.1398-9995.2007.01557.x